Argenx

This study tests an experimental drug called empasiprubart in people with a specific type of generalized myasthenia gravis (gMG) who have AChR antibodies. The goal is to see if the drug is safe and can improve symptoms like muscle weakness that affect daily activities. Participan…

This study tests a new medicine called empasiprubart in teenagers aged 12 to 17 who have a rare nerve disease called CIDP. The goal is to find the right dose and see if the drug is safe and helps control the disease. Participants will receive the drug for about 27 months and be f…

This early-stage trial tests an experimental drug called empasiprubart in 60 adults with multifocal motor neuropathy (MMN), a rare condition that causes muscle weakness. The drug is given as an IV infusion, and researchers will use ultrasound to measure nerve thickness, along wit…

This study tests an investigational drug called efgartigimod for adults with Graves' disease whose thyroid levels are still high despite taking standard antithyroid medications. About 230 participants will receive either the drug or a placebo as a shot under the skin. The goal is…

This Phase 2 trial tests efgartigimod PH20 SC, a drug that lowers harmful antibodies, in 170 adults and teens with autoimmune encephalitis (AIE). Participants receive either the drug or a placebo, and researchers measure changes in disability and symptoms over up to 3 years. The …

This study tests a drug called efgartigimod, given as a shot under the skin, for adults with Graves' disease whose thyroid levels are still too high despite taking standard antithyroid drugs. About 230 people will take part, and some will get the drug while others get a placebo. …